%0 Case Reports
%T A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab.
%A Zhang L
%A Wang S
%A Chen Q
%A Xiang L
%J J Dermatolog Treat
%V 34
%N 1
%D 2023 Dec
%M 37968922
%F 3.23
%R 10.1080/09546634.2023.2253943
%X Inherited epidermolysis bullosa is a heterogeneous group of hereditary skin diseases characterized by skin (mucosa) fragility, which leads to blistering. Junctional epidermolysis bullosa is associated with mutations in genes expressing proteins of the dermo-epidermal junction. Dupilumab, an antibody that directly targets interleukin (IL)-4 receptor alpha, may be an effective treatment for dystrophic epidermolysis bullosa. We describe a case of junctional epidermolysis bullosa that improved with dupilumab.